Biotechnology & Drugs news, Biotechnology & Drugs industry, industry News

▮ More

Notable Earnings To Watch On July 23 - AN, JBLU, BIIB, CMG, KO, HOG, HAS, TXN

PetMed Express Inc. Bottom Line Retreats In Q1

Intec Says Phase 3 Trial Did Not Achieve Statistical Superiority To Sinemet

FDA Says No To BHVN, Detraxi Eyeing Solution For Blood Shortage, MRKR On Watch

Healthcare IPOs For The Week Ahead

Notable Earnings On July 22 - AMTD, BRO, WHR, HAL, CE, STLD

Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

Gilead Sciences Licenses Three Preclinical Antiviral Programs From Novartis

BMY To Explore Stivarga/Opdivo Combo, MYOK Ahead Of Timeline, UNH On Watch

Sartorius Stedim Biotech H1 Sales Revenue Up 19.0% To EUR 709.3 Mln

5 Top Losers In Healthcare Sector (LIFE, SENS, GHSI…)

5 Top Gainers In Healthcare Sector (OTLK, NEPT, EOLS...)

Intuitive Surgical Inc. Q2 adjusted earnings Beat Estimates

CTI BioPharma To Initiate PACIFICA Phase 3 Trial In Q3 - Quick Facts

Bayer, Bristol-Myers Squibb, Ono Pharma Enter Into Clinical Collaboration

Bayer, Bristol-Myers Squibb And Ono Pharmaceutical Enter Clinical Collaboration

Unitedhealth Group, Inc. Q2 adjusted earnings Beat Estimates

FDA Nod For MRK's Antibiotic; DRRX Awaits Big Day In Dec., Airxpanders Goes Bust

Novartis Q2 Profit Declines; But Raises FY19 Outlook - Quick Facts

Novartis Q2 EPS From Cont Ops $0.91 Vs $3.32 Last Year

5 Top Losers In Healthcare Sector (XBIO, SENS, FTSV...)

Boeing Hires 9/11 Compensation Fund Lawyer To Handle 737 Max Claims

5 Top Gainers In Healthcare Sector (SCPH, SGEN, ANIX…)

Amarin Stock Down On Possible AdCom Meeting By FDA Related To Vascepa

CVS Health Initiates Clinical Trial For New Home Hemodialysis Device

Industries >>

Biotechnology & Drugs News

Gilead Sciences Licenses Three Preclinical Antiviral Programs From Novartis

Sartorius Stedim Biotech H1 Sales Revenue Up 19.0% To EUR 709.3 Mln

Bayer, Bristol-Myers Squibb And Ono Pharmaceutical Enter Clinical Collaboration

Novartis Q2 EPS From Cont Ops $0.91 Vs $3.32 Last Year